83.87
price down icon0.97%   -0.82
after-market After Hours: 83.50 -0.37 -0.44%
loading
Astrazeneca PLC stock is traded at $83.87, with a volume of 5.02M. It is down -0.97% in the last 24 hours and up +9.95% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$84.69
Open:
$84.86
24h Volume:
5.02M
Relative Volume:
1.01
Market Cap:
$260.11B
Revenue:
$56.53B
Net Income/Loss:
$8.32B
P/E Ratio:
31.50
EPS:
2.6622
Net Cash Flow:
$8.49B
1W Performance:
-0.76%
1M Performance:
+9.95%
6M Performance:
+24.09%
1Y Performance:
+7.17%
1-Day Range:
Value
$83.78
$85.18
1-Week Range:
Value
$83.09
$85.18
52-Week Range:
Value
$61.24
$86.57

Astrazeneca PLC Stock (AZN) Company Profile

Name
Name
Astrazeneca PLC
Name
Phone
44 20 3749 5000
Name
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
Employee
61,100
Name
Twitter
@AstraZeneca
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
83.87 262.58B 56.53B 8.32B 8.49B 2.6622

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-16-25 Downgrade Deutsche Bank Hold → Sell
Apr-15-25 Initiated Exane BNP Paribas Outperform
Feb-13-25 Upgrade UBS Neutral → Buy
Feb-12-25 Initiated Morgan Stanley Overweight
Nov-20-24 Upgrade UBS Sell → Neutral
Nov-06-24 Upgrade Deutsche Bank Sell → Hold
Sep-13-24 Downgrade Deutsche Bank Hold → Sell
May-30-24 Initiated Goldman Buy
Apr-16-24 Upgrade Deutsche Bank Sell → Hold
Feb-08-24 Downgrade Deutsche Bank Hold → Sell
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Sell
Jan-03-24 Downgrade Jefferies Buy → Hold
Dec-18-23 Initiated HSBC Securities Buy
Sep-25-23 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-12-23 Upgrade UBS Neutral → Buy
Jul-05-23 Downgrade Deutsche Bank Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-05-23 Initiated BMO Capital Markets Outperform
Sep-15-22 Downgrade Credit Suisse Outperform → Neutral
Sep-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-29-22 Upgrade Argus Hold → Buy
Jun-14-22 Downgrade UBS Buy → Neutral
Feb-11-22 Upgrade DZ Bank Sell → Hold
Dec-07-21 Downgrade Jefferies Buy → Hold
Aug-12-21 Resumed JP Morgan Overweight
Apr-12-21 Downgrade Argus Buy → Hold
Mar-16-21 Upgrade Jefferies Hold → Buy
Feb-25-21 Upgrade UBS Neutral → Buy
Jan-15-21 Initiated Deutsche Bank Buy
Dec-07-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20 Upgrade UBS Sell → Neutral
Nov-11-20 Upgrade HSBC Securities Reduce → Hold
Sep-29-20 Initiated Berenberg Buy
Nov-22-19 Initiated SVB Leerink Outperform
Oct-25-19 Upgrade Liberum Hold → Buy
Apr-02-19 Downgrade UBS Neutral → Sell
Feb-05-19 Initiated Exane BNP Paribas Outperform
Jan-25-19 Upgrade Shore Capital Hold → Buy
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Aug-16-18 Downgrade Jefferies Buy → Hold
Mar-19-18 Upgrade Jefferies Hold → Buy
Feb-06-18 Reiterated Leerink Partners Mkt Perform
Feb-05-18 Reiterated Bernstein Outperform
Jan-18-18 Reiterated Leerink Partners Mkt Perform
Dec-29-17 Upgrade JP Morgan Neutral → Overweight
Oct-16-17 Upgrade Credit Suisse Neutral → Outperform
Sep-25-17 Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17 Upgrade Bernstein Mkt Perform → Outperform
View All

Astrazeneca PLC Stock (AZN) Latest News

pulisher
02:24 AM

Will AstraZeneca PLC (ZEG) stock profit from AI boomGap Up & Low Risk High Win Rate Stock Picks - newser.com

02:24 AM
pulisher
01:46 AM

How AstraZeneca PLC (Common Stock) (ZEGA) stock performs during market turbulence2025 Geopolitical Influence & Detailed Earnings Play Alerts - newser.com

01:46 AM
pulisher
01:30 AM

Will AstraZeneca PLC (ZEG) stock test record highs in 2025Weekly Risk Summary & Weekly Setup with High ROI Potential - newser.com

01:30 AM
pulisher
12:47 PM

Has AstraZeneca PLC Depositary Receipt formed a bullish divergence2025 Price Action Summary & Long-Term Growth Plans - newser.com

12:47 PM
pulisher
Oct 20, 2025

Will Precidian ETFs Trust AstraZeneca PLC stock hit Wall Street targetsPortfolio Return Report & Free Accurate Trade Setup Notifications - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Is AstraZeneca PLC Depositary Receipt meeting your algorithmic filter criteriaPortfolio Value Summary & Long-Term Growth Plans - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Top Research Reports for AstraZeneca, RTX & Applied Materials - sharewise.com

Oct 20, 2025
pulisher
Oct 20, 2025

Risk vs reward if holding onto AstraZeneca PLC Depositary Receipt2025 EndofYear Setup & AI Enhanced Execution Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

AstraZeneca, Gilead vie for edge in race to treat tough breast cancer - The Economic Times

Oct 20, 2025
pulisher
Oct 20, 2025

Why ETFs are accumulating AstraZeneca PLC (ZEG) stockPortfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Why AstraZeneca PLC (ZEG) stock stays on buy listsMarket Risk Summary & Proven Capital Preservation Methods - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

ESMO 25: AstraZeneca And Lilly Turn Up Heat In FRa Antibody-Drug Conjugates - Citeline News & Insights

Oct 20, 2025
pulisher
Oct 20, 2025

Can AstraZeneca PLC Depositary Receipt stock sustain revenue growth2025 Pullback Review & Low Risk Growth Stock Ideas - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

AstraZeneca, Daiichi’s Datroway excels in hard-to-treat breast cancer - BioPharma Dive

Oct 20, 2025
pulisher
Oct 20, 2025

Is AstraZeneca PLC (Common Stock) (ZEGA) stock inflation resilientOil Prices & Community Verified Trade Signals - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock - sharewise.com

Oct 20, 2025
pulisher
Oct 20, 2025

AstraZeneca PLC Depositary Receipt stock momentum explainedQuarterly Portfolio Summary & Growth-Oriented Investment Plans - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

AstraZeneca receives positive CHMP opinion for subcutaneous Saphnelo in EU - Investing.com

Oct 20, 2025
pulisher
Oct 20, 2025

Is AstraZeneca PLC Depositary Receipt stock ready for a breakout - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

US FDA OKs Tezspire in CRSwNP, expanding AstraZeneca’s label beyond asthma - Stock Titan

Oct 20, 2025
pulisher
Oct 20, 2025

AZN wins EU CHMP support for once-weekly SC Saphnelo; 40,000 patients treated - Stock Titan

Oct 20, 2025
pulisher
Oct 20, 2025

Astra, Gilead Vie for Edge in Race to Treat Tough Triple-Negative Breast Cancer - Bloomberg.com

Oct 20, 2025
pulisher
Oct 20, 2025

How to build a custom watchlist for AstraZeneca PLC Depositary ReceiptJuly 2025 Recap & High Accuracy Investment Entry Signals - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Prediction: This Unstoppable Vanguard ETF Will Beat the S&P 500 Again in 2026 - The Motley Fool

Oct 20, 2025
pulisher
Oct 20, 2025

Can Precidian ETFs Trust AstraZeneca PLC stock deliver double digit returns2025 Top Decliners & Real-Time Price Movement Reports - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

AstraZeneca presents 'major results' for Datroway in breast cancer - MarketScreener

Oct 20, 2025
pulisher
Oct 20, 2025

Will AstraZeneca PLC (ZEG) stock benefit from Fed rate cuts2025 Performance Recap & Reliable Intraday Trade Plans - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Pattern recognition hints at AstraZeneca PLC Depositary Receipt upsideProfit Target & Trade Opportunity Analysis - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

REGAstraZeneca PLCUS FDA Approves Tezspire in CRSwNP - TradingView

Oct 20, 2025
pulisher
Oct 20, 2025

AstraZeneca and Daiichi’s drug Enhertu raises hopes for early breast cancer cure - Mint

Oct 20, 2025
pulisher
Oct 20, 2025

AstraZeneca and Daiichi’s Drug Enhertu Raises Hopes for Early Breast Cancer Cure - Bloomberg.com

Oct 20, 2025
pulisher
Oct 20, 2025

Why AstraZeneca PLC Depositary Receipt stock remains undervaluedGDP Growth & Weekly High Conviction Trade Ideas - newser.com

Oct 20, 2025
pulisher
Oct 19, 2025

AstraZeneca, Daiichi Sankyo's Early Breast Cancer Drug Shows Positive Results in Late-stage Trial - MarketScreener

Oct 19, 2025
pulisher
Oct 19, 2025

AstraZeneca, Daiichi Sankyo Report Positive Results from Phase 3 Trial of Datroway - MarketScreener

Oct 19, 2025
pulisher
Oct 19, 2025

AstraZeneca (AZN) Reports Success in Breast Cancer Trial with En - GuruFocus

Oct 19, 2025
pulisher
Oct 19, 2025

AstraZeneca (AZN) Reports Promising Results in Breast Cancer Tri - GuruFocus

Oct 19, 2025
pulisher
Oct 19, 2025

AstraZeneca's Datroway extends survival in aggressive breast cancer - Reuters

Oct 19, 2025
pulisher
Oct 19, 2025

AstraZeneca, Amgen Secure US FDA Nod for CRSwNP Treatment - MarketScreener

Oct 19, 2025
pulisher
Oct 18, 2025

AstraZeneca PLC Depositary Receipt recovery potential after sell offQuarterly Profit Review & Weekly Breakout Stock Alerts - newser.com

Oct 18, 2025
pulisher
Oct 18, 2025

AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Bre - GuruFocus

Oct 18, 2025
pulisher
Oct 18, 2025

Will AstraZeneca PLC Depositary Receipt stock gain from strong economyGap Up & Long Hold Capital Preservation Plans - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

Why global investors buy AstraZeneca PLC (Common Stock) (ZEGA) stockJuly 2025 Intraday Action & Stepwise Swing Trade Plans - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment - Reuters

Oct 18, 2025
pulisher
Oct 18, 2025

Astrazeneca says positive results from Destiny-Breast11 Phase III trial - MarketScreener

Oct 18, 2025
pulisher
Oct 18, 2025

Can AstraZeneca PLC (ZEG) stock reach $200 price target2025 Earnings Impact & Weekly Stock Breakout Alerts - nchmf.gov.vn

Oct 18, 2025
pulisher
Oct 18, 2025

How to monitor AstraZeneca PLC Depositary Receipt with trend dashboardsWeekly Volume Report & AI Forecast for Swing Trade Picks - newser.com

Oct 18, 2025
pulisher
Oct 18, 2025

Block Trades: Why AstraZeneca PLC Depositary Receipt stock remains undervalued2025 Pullback Review & Stock Timing and Entry Methods - nchmf.gov.vn

Oct 18, 2025

Astrazeneca PLC Stock (AZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
Cap:     |  Volume (24h):